FDA-cleared profile

Aquilion Precision (TSX-304A/4) V10.10 with AiCE

Canon Medical Systems Corporation · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Aquilion Precision TSX-304A/4 V10.10 with AiCE is a CT system for cross-sectional imaging of the labeled abdomen, pelvis, chest, cardiac, extremity, and head examinations, including the cleared FIRST and AiCE image-processing functions.

Clinical role
CT acquisition, reconstruction, visualization, image processing, and examination planning under professional review.
Images and patients
CT/CTA · Abdomen, pelvis, chest, cardiac structures, extremities, and head
Key limitation
Keep in mind: Use only the cleared populations, protocols, reconstructions, applications, and patient-size limits; local dose, image-quality, geometry, and downstream acceptance remain necessary.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Aquilion Precision TSX-304A/4 V10.10 with AiCE is a CT system for cross-sectional imaging of the labeled abdomen, pelvis, chest, cardiac, extremity, and head examinations, including the cleared FIRST and AiCE image-processing functions.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Abdomen, pelvis, chest, cardiac structures, extremities, and head Input: X-ray projection data acquired under supported patient, protocol, contrast, dose, and reconstruction conditions.
  • Who uses it?Intended users: Qualified CT technologists and trained interpreting or treating physicians.
  • What does the software produce?Output: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.
  • What is its most important limitation?Key limitation: Use only the cleared populations, protocols, reconstructions, applications, and patient-size limits; local dose, image-quality, geometry, and downstream acceptance remain necessary.

Clinical takeaway. Clinical role: Aquilion Precision TSX-304A/4 V10.10 with AiCE is a CT system for cross-sectional imaging of the labeled abdomen, pelvis, chest, cardiac, extremity, and head examinations, including the cleared FIRST and AiCE image-processing functions.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports phantom bench testing of image quality (CNR, CT number accuracy, uniformity, MTF), a noise texture analysis, and a spatial resolution study supporting improvement claims of 16.5 lp/cm (Body), 10.5 lp/cm (Cardiac) and 15 lp/cm (Lung) in HR mode versus hybrid iterative reconstruction at the same dose; another study found HR mode with AiCE dose neutral relative to AIDR normal resolution mode. An American Board Certified Radiologist confirmed representative clinical images were of diagnostic quality. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Aquilion Precision TSX-304A/4 V10.10 with AiCE is a CT system for cross-sectional imaging of the labeled abdomen, pelvis, chest, cardiac, extremity, and head examinations, including the cleared FIRST and AiCE image-processing functions.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
CT acquisition, reconstruction, visualization, image processing, and examination planning under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
X-ray projection data acquired under supported patient, protocol, contrast, dose, and reconstruction conditions.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital and outpatient CT, interventional, oncology, or radiotherapy departments within the cleared scope.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified CT technologists and trained interpreting or treating physicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use only the cleared populations, protocols, reconstructions, applications, and patient-size limits; local dose, image-quality, geometry, and downstream acceptance remain necessary.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports phantom bench testing of image quality (CNR, CT number accuracy, uniformity, MTF), a noise texture analysis, and a spatial resolution study supporting improvement claims of 16.5 lp/cm (Body), 10.5 lp/cm (Cardiac) and 15 lp/cm (Lung) in HR mode versus hybrid iterative reconstruction at the same dose; another study found HR mode with AiCE dose neutral relative to AIDR normal resolution mode. An American Board Certified Radiologist confirmed representative clinical images were of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CT image quality metrics were performed, utilizing phantoms, to assess Contrast-to- Noise Ratios (CNR), CT Number Accuracy, Uniformity, Slice Sensitivity Profile (SSPz), Modulation Transfer Function (MTF)-Wire" … "An analysis of the NPS and kurtosis values for FBP, FIRST and AiCE was conducted and the results of the study support claims that AiCE images have a more natural noise texture compared to FIRST images". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports phantom bench testing of image quality (CNR, CT number accuracy, uniformity, MTF), a noise texture analysis, and a spatial resolution study supporting improvement claims of 16.5 lp/cm (Body), 10.5 lp/cm (Cardiac) and 15 lp/cm (Lung) in HR mode versus hybrid iterative reconstruction at the same dose; another study found HR mode with AiCE dose neutral relative to AIDR normal resolution mode. An American Board Certified Radiologist confirmed representative clinical images were of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CT image quality metrics were performed, utilizing phantoms, to assess Contrast-to- Noise Ratios (CNR), CT Number Accuracy, Uniformity, Slice Sensitivity Profile (SSPz), Modulation Transfer Function (MTF)-Wire" … "An analysis of the NPS and kurtosis values for FBP, FIRST and AiCE was conducted and the results of the study support claims that AiCE images have a more natural noise texture compared to FIRST images". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K220986 FDA evidence package for Aquilion Precision (TSX-304A/4) V10.10 with AiCE

  • DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
  • PopulationAbdomen, pelvis, chest, cardiac structures, extremities, and head
  • Scopeexact submission
  • Tested versionAquilion Precision (TSX-304A/4) V10.10 with AiCE configuration described in K220986
  • IndependenceSponsor or vendor study

K220986

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220986 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray projection data acquired under supported patient, protocol, contrast, dose, and reconstruction conditions.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K220986: Aquilion Precision (TSX-304A/4) V10.10 with AiCE

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Source context, not route validation: The exact FDA package describes Aquilion Precision as a helical CT scanner consisting of a gantry, couch and a console used for data processing and display, incorporating AiCE reconstruction technology. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "helical CT scanner, consisting of a gantry, couch and a console used for data processing and display." … "the subject device incorporates the latest reconstruction technology, AiCE (Advanced intelligent Clear-IQ Engine)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K220986: Aquilion Precision (TSX-304A/4) V10.10 with AiCE

  4. Returned objects

    Source context, not route validation: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K220986: Aquilion Precision (TSX-304A/4) V10.10 with AiCE

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional CT images, reformats, measurements, attenuation maps, and planning datasets for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K220986: Aquilion Precision (TSX-304A/4) V10.10 with AiCE

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Aquilion Precision as a helical CT scanner consisting of a gantry, couch and a console used for data processing and display, incorporating AiCE reconstruction technology. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "helical CT scanner, consisting of a gantry, couch and a console used for data processing and display." … "the subject device incorporates the latest reconstruction technology, AiCE (Advanced intelligent Clear-IQ Engine)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.

Training
Only qualified ct technologists and trained interpreting or treating physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K220986 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only the cleared populations, protocols, reconstructions, applications, and patient-size limits; local dose, image-quality, geometry, and downstream acceptance remain necessary.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K220986 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only the cleared populations, protocols, reconstructions, applications, and patient-size limits; local dose, image-quality, geometry, and downstream acceptance remain necessary.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K220986 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only the cleared populations, protocols, reconstructions, applications, and patient-size limits; local dose, image-quality, geometry, and downstream acceptance remain necessary.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. computed tomography imaging system limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220986
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Abdomen, pelvis, chest, cardiac structures, extremities, and head
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-09-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K220986: Aquilion Precision (TSX-304A/4) V10.10 with AiCE

    U.S. Food and Drug Administration - Published 2022-09-12 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Canon Medical: Medical Imaging Cybersecurity

    Canon Medical Systems USA - Accessed 2026-10-26

    Scope: security

Research history

  1. K220986 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260324

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc.

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Modality
CT/CTA
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Decision
2026-05-22
FDA-cleared K253596

Aquilion ONE (TSX-308A/TSX-306A) V2.0

Canon Medical Systems Corporation

Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.

Modality
CT/CTA
Anatomy
Whole body; head; chest; abdomen; pelvis; heart; extremities; and inner ear
Decision
2026-05-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history